IMT 009
Alternative Names: IMT-009Latest Information Update: 27 Apr 2026
At a glance
- Originator Immunitas Therapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Natural killer cell modulators; NK cell lectin-like receptor subfamily B inhibitors; T lymphocyte modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Lymphoma; Solid tumours
- No development reported Glioma
Most Recent Events
- 17 Apr 2026 Efficacy and adverse event data from a phase I/IIa trial in Solid tumour released by Immunitas Therapeutics
- 28 Mar 2025 No recent reports of development identified for preclinical development in Glioma in USA (Parenteral)
- 10 Apr 2024 Interim pharmacodynamics data from a preclinical studies in Solid tumours and Lymphoma released by (Company)